Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ImageneBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ImageneBio's regulatory disclosures and financial reporting.
ImageneBio, Inc. director Bonita P. David received a grant of stock options covering 15,600 shares of Common Stock. The options have an exercise price of $5.45 per share and expire on June 16, 2036. They vest in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control as defined in ImageneBio’s 2025 Equity Incentive Plan. Following this award, the filing shows David holding 15,600 options directly, with no open-market buying or selling reported.
ImageneBio, Inc. filed a prospectus supplement registering 2,508,337 shares of Common Stock for resale by the selling stockholders. The supplement attaches portions of a Form 8-K reporting that stockholders approved an amendment to the 2025 Equity Incentive Plan increasing the plan reserve by 850,000 shares. The filing states 11,279,130 shares outstanding as of April 28, 2026 and notes a last reported sales price of $5.45 per share on June 16, 2026. The Amended Plan also describes an automatic annual increase equal to 5% of specified share counts beginning January 1, 2027.
ImageneBio, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amended and restated 2025 Equity Incentive Plan that increases the shares of common stock authorized for issuance under the plan by 850,000 shares and adjusts how the automatic annual share reserve increase is calculated.
They also elected two Class II directors, David P. Bonita, M.D. and Joseph P. Slattery, to serve until the 2029 annual meeting, and ratified PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026. There were 11,279,130 shares of voting common stock outstanding as of the April 28, 2026 record date.
ImageneBio, Inc. Schedule 13G/A discloses that a group of related entities led by Biotechnology Value Fund and Mark N. Lampert collectively report beneficial ownership positions in the company's common stock. The filing lists specific holdings as of March 31, 2026 and cites an outstanding share base of 11,184,995 shares as of March 2, 2026.
The filing itemizes holdings by entity: BVF 593,189 shares (≈5.3%), BVF2 433,269 shares (≈3.9%), Trading Fund OS 66,808 shares (<1%), and aggregate positions attributed across affiliated entities up to 1,110,002 shares (≈9.9%). Voting and dispositive power are disclosed as shared among the listed reporting persons.
Blue Owl Capital Holdings filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership in ImageneBio, Inc.
The filing states the Reporting Person beneficially owns 959,337 shares of Common Stock, equal to 8.51% of the class, calculated using 11,279,130 shares outstanding as of April 30, 2026 (per the issuer's 10-Q filed May 7, 2026). The cover page lists sole voting and dispositive power over the 959,337 shares. The statement includes a Rule 13d-4 declaration that filing is not an admission of beneficial ownership.
ImageneBio, Inc. files a prospectus supplement to register 2,508,337 shares of Common Stock for offer and resale by identified selling stockholders. The supplement updates the April 2, 2026 prospectus with selected Form 10-Q information and notes a last reported sale price of $6.08 per share on May 6, 2026.
The registration relates to resale or other dispositions "from time to time by the selling stockholders" under Registration No. 333-290108; the supplement is dated May 7, 2026 and references the Prospectus dated April 2, 2026.
ImageneBio, Inc. registers 2,508,337 shares of Common Stock for resale by the selling stockholders identified in the prospectus supplement. The resale prospectus supplement updates the Form S-1 registration (No. 333-290108) and incorporates specified portions of the company’s Form 10-Q filed May 7, 2026.
The Common Stock trades on the Nasdaq Capital Market under the symbol IMA; the last reported sales price on May 6, 2026 was $6.08 per share. The prospectus supplement states proceeds from resales will be received by the selling stockholders, not the issuer.
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on immunological and inflammatory diseases, led by its anti-OX40 antibody IMG-007 for atopic dermatitis and alopecia areata. For the three months ended March 31, 2026, it reported a net loss of $10.6 million, compared with $6.1 million a year earlier, as research and development expenses rose to $6.0 million and general and administrative expenses increased to $6.1 million.
Cash, cash equivalents and marketable securities totaled $117.2 million as of March 31, 2026. In April 2026, the company raised an additional $30.0 million through a private placement of pre-funded warrants to purchase up to 5,770,335 shares of common stock at a purchase price of $5.199 per warrant share and an exercise price of $0.001 per share. Management believes this funding, together with existing resources, can support operations for at least 12 months.
The company completed a reverse merger with Ikena Oncology and divested its non-OX40 assets in 2025, leaving IMG-007 as its sole clinical asset. A multi-country Phase 2b dose-finding study in atopic dermatitis is underway, with topline data expected in the fourth quarter of 2027, and a Phase 2 study in alopecia areata is planned to start by the end of 2026, with initial data anticipated in 2028.
ImageneBio, Inc. reported first quarter 2026 results and highlighted progress for its lead OX40 antibody IMG-007 in atopic dermatitis and alopecia areata. License revenue was $0 versus $800,000 a year earlier as the company focuses on clinical development.
Research and development expenses rose to $6.0 million from $4.0 million, and general and administrative expenses increased to $6.1 million from $2.8 million. Net loss widened to $10.6 million from $9.1 million, reflecting higher operating costs.
Imagene ended March 31, 2026 with $117.2 million in cash, cash equivalents, and marketable securities and subsequently completed a $30 million private placement of pre-funded warrants. The company states this financing extends its cash runway into the first quarter of 2028 while it advances the Phase 2b ADAPTIVE trial of IMG-007 in atopic dermatitis and continues development in alopecia areata.